Sequence conservation in Plasmodium falciparum α-helical coiled coil domains proposed for vaccine development

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Kulangara, Caroline ^a   Kajava, Andrey V ^b   Corradin, Giampietro ^c   Felger, Ingrid ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Centre National de la Recherche Scientifique   (France)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; PEPTIDE; PROTOZOAL PROTEIN; PROTOZOAL VACCINE;

ALPHA HELIX; ARTICLE; COILED BODY; GENE SEQUENCE; GENETIC CONSERVATION; GENETIC VARIABILITY; IN VITRO STUDY; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; PROTEIN MOTIF; PROTOZOAL GENETICS; PROTOZOON; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINE PRODUCTION; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG DESIGN; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PAPUA NEW GUINEA; POPULATION GENETICS; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; TANZANIA;

PLASMODIUM FALCIPARUM;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CONSERVED SEQUENCE; DRUG DESIGN; GENETICS, POPULATION; MOLECULAR SEQUENCE DATA; PAPUA NEW GUINEA; PEPTIDES; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SEQUENCE ALIGNMENT; TANZANIA;

EID: 66249119722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005419     Document Type: Article

References (38)

1. Good MF (2005) Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 21: 29-34.
2. Kemp DJ, Coppel RL, Anders RF (1987) Repetitive proteins and genes of malaria. Annu Rev Microbiol 41: 181-208.
3. Mu J, Awadalla P, Duan J, McGee KM, Keebler J, et al. (2007) Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat Genet 39: 126-130.
4. Saul A, Fay MP (2007) Human immunity and the design of multi-component, single target vaccines. PLoS ONE 2: e850.
5. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, et al. (2002) A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185: 820-827.
6. Fluck C, Smith T, Beck HP, Irion A, Betuela I, et al. (2004) Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun 72: 6300-6305.
7. Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, et al. (2008) Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE 3: e2830.
8. Enosse S, Dobano C, Quelhas D, Aponte JJ, Lievens M, et al. (2006) RTS, S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials 1: e5.
9. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, et al. (1999) Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17: 3145-3159.
10. Polley SD, Tetteh KK, Lloyd JM, Akpogheneta OJ, Greenwood BM, et al. (2007) Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 195: 279-287.
11. Plebanski M, Lee EA, Hill AV (1997) Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein. Parasitology 115 Suppl: S55-66.
12. Pouniotis DS, Proudfoot O, Minigo G, Hanley JL, Plebanski M (2004) Malaria parasite interactions with the human host. J Postgrad Med 50: 30-34.
13. Villard V, Agak GW, Frank G, Jafarshad A, Servis C, et al. (2007) Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS ONE 2: e645.
14. Corradin G, Villard V, Kajava AV (2007) Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens. Endocr Metab Immune Disord Drug Targets 7: 259-265.
15. Lu SM, Hodges RS (2002) A de novo designed template for generating conformation-specific antibodies that recognize alpha-helices in proteins. J Biol Chem 277: 23515-23524.
16. Walshaw J, Woolfson DN (2001) Open-and-shut cases in coiled-coil assembly: alpha-sheets and alpha-cylinders. Protein Sci 10: 668-673.
17. Burkhard P, Stetefeld J, Strelkov SV (2001) Coiled coils: a highly versatile protein folding motif. Trends Cell Biol 11: 82-88.
18. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, et al. (2007) A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 178: 3099-3106.
19. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P (1995) Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182: 409-418.
20. Trager W, Jensen JB (1997) Continuous culture of Plasmodium falciparum: its impact on malaria research. Int J Parasitol 27: 989-1006.
21. Irion A, Felger I, Abdulla S, Smith T, Mull R, et al. (1998) Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children. Trop Med Int Health 3: 490-497.
22. Marfurt J, Mueller I, Sie A, Maku P, Goroti M, et al. (2007) Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg 77: 947-954.
23. Bucher P, Karplus K, Moeri N, Hofmann K (1996) A flexible motif search technique based on generalized profiles. Comput Chem 20: 3-23.
24. Berman H, Henrick K, Nakamura H (2003) Announcing the worldwide Protein Data Bank. Nat Struct Biol 10: 980.
25. Volkman SK, Sabeti PC, DeCaprio D, Neafsey DE, Schaffner SF, et al. (2007) A genome-wide map of diversity in Plasmodium falciparum. Nat Genet 39: 113-119.
26. Franks S, Baton L, Tetteh K, Tongren E, Dewin D, et al. (2003) Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun 71: 3485-3495.
27. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, et al. (2000) A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 6: 689-692.
28. Osier FH, Polley SD, Mwangi T, Lowe B, Conway DJ, et al. (2007) Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. Parasite Immunol 29: 387-394.
29. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, et al. (2005) A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2: e344.
30. Singh S, Soe S, Mejia JP, Roussilhon C, Theisen M, et al. (2004) Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 190: 1010-1018.
31. Lamb D, Schuttelkopf AW, van Aalten DM, Brighty DW (2008) Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope. Retrovirology 5: 70.
32. Bai T, Becker M, Gupta A, Strike P, Murphy VJ, et al. (2005) Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci U S A 102: 12736-12741.
33. Crewther PE, Matthew ML, Flegg RH, Anders RF (1996) Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 64: 3310-3317.
34. Felger I, Irion A, Steiger S, Beck HP (1999) Genotypes of merozoite surface protein 2 of Plasmodium falciparum in Tanzania. Trans R Soc Trop Med Hyg 93 Suppl 1: 3-9.
35. Tetteh KK, Cavanagh DR, Corran P, Musonda R, McBride JS, et al. (2005) Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen. Infect Immun 73: 5928-5935.
36. Vekemans J, Ballou WR (2008) Plasmodium falciparum malaria vaccines in development. Expert Rev Vaccines 7: 223-240.
37. Genton B (2008) Malaria vaccines: a toy for travelers or a tool for eradication? Expert Rev Vaccines 7: 597-611.
38. Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, et al. (2006) Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24: 4709-4715.